4-Hydroxytamoxifen Induces Autophagic Death through K-Ras Degradation

Latika Kohli1,2, Niroop Kaza1, Tatjana Coric3, Stephanie J. Byer1, Nicole M. Brossier2,4, Barbara J. Klocke1, Mary-Ann Bjornsti3, Steven L. Carroll1, and Kevin A. Roth1

Abstract

Tamoxifen is widely used to treat estrogen receptor–positive breast cancer. Recent findings that tamoxifen and its derivative 4-hydroxytamoxifen (OHT) can exert estrogen receptor–independent cytotoxic effects have prompted the initiation of clinical trials to evaluate its use in estrogen receptor–negative malignancies. For example, tamoxifen and OHT exert cytotoxic effects in malignant peripheral nerve sheath tumors (MPNST) where estrogen is not involved. In this study, we gained insights into the estrogen receptor–independent cytotoxic effects of OHT by studying how it kills MPNST cells. Although caspases were activated following OHT treatment, caspase inhibition provided no protection from OHT-induced death. Rather, OHT-induced death in MPNST cells was associated with autophagic induction and attenuated by genetic inhibition of autophagic vacuole formation. Mechanistic investigations revealed that OHT stimulated autophagic degradation of K-Ras, which is critical for survival of MPNST cells. Similarly, we found that OHT induced K-Ras degradation in breast, colon, glioma, and pancreatic cancer cells. Our findings describe a novel mechanism of autophagic death triggered by OHT in tumor cells that may be more broadly useful clinically in cancer treatment. Cancer Res; 73(14); 4395–405. ©2013 AACR.

Introduction

The triphenylethylene compound tamoxifen is a nonsteroidal selective estrogen receptor modulator that is used as the first-line treatment for estrogen receptor–positive breast cancer (1). While its principal target is the estrogen receptor (2), tamoxifen, at micromolar concentrations, exerts cytotoxic effects that are not reversed by estrogen addition (3). In fact, multiple non–estrogen receptor-mediated mechanisms have been implicated in death induced by tamoxifen and its hydroxylated derivative 4-hydroxytamoxifen (OHT). These mechanisms include changes in intracellular calcium (4); modulation of protein kinase C (PKC; refs. 5, 6); changes in calmodulin activity (7); and signaling through mitogen-activated protein kinases (MAPK; ref. 8). The diverse target range of tamoxifen and its estrogen receptor-independent effects have prompted its inclusion in clinical trials for multiple solid tumor types including estrogen receptor-negative malignancies (9, 10). In patients with largely inoperable and recurrent malignant gliomas, there seems to be a consistent relationship between higher doses of tamoxifen and higher radiographic response rates and longer survival (11). Tamoxifen has also been shown to augment the effects of cisplatin (12). However, a meta-analysis of 6 randomized trials for metastatic melanoma reveals no significant change in the survival rates following tamoxifen treatment (13). Currently, there are ongoing trials using tamoxifen in combination with chemotherapy for stage 3 melanoma and metastatic bladder cancer.

Malignant peripheral nerve sheath tumors (MPNST) are aggressive sarcomas that have a poor prognosis, in part because no effective chemotherapeutic options are available (14, 15). MPNSTs are the most common malignancy associated with neurofibromatosis type 1 (NF1; ref. 16). As the NF1 gene codes for neurofibromin, a Ras GTPase-activating protein (GAP), loss of this gene results in Ras hyperactivation in NF1-associated tumor types (17). Recently, we showed that tamoxifen could potently inhibit MPNST growth in vivo (18). While MPNST cell lines express estrogen receptors, ablation of these receptors had no effect on OHT-induced cytotoxicity, indicating an estrogen receptor-independent mechanism of action. Therefore, the overall goal of this study was to delineate the mechanism of OHT-induced cytotoxicity in MPNST cells.

OHT has been reported to induce apoptosis in tumor cells through activation of multiple upstream pathways. However, in addition to apoptotic features, cells dying in response to OHT treatment also display large-scale autophagic vacuole (AV) accumulation, suggesting a possible role for autophagy in the regulation of OHT-induced death (19, 20). Autophagy is a cellular catabolic pathway that targets long-lived proteins and cellular content for degradation and mediates
their recycling. Therapy-induced autophagy has been previously implicated in the regulation of cancer cell survival (21). It can play a prosurvival role and mediate resistance to therapy (22–25). Alternatively, autophagy can initiate and directly cause cell death (26). However, the precise mechanism by which therapy-induced autophagy causes cell death is poorly defined.

In this study, we show that OHT-induced death of MPNST cells is mediated by autophagy induction, not caspase-dependent apoptosis. This is achieved, at least in part, through degradation of K-Ras, a critical prosurvival protein previously identified as a regulator of tamoxifen sensitivity (27). Interestingly, the Ras pathway has been implicated as a novel mechanism for autophagy mediated death and also a determinant of the clinical effectiveness of tamoxifen therapy in patients with breast cancer (28). Our findings identify a novel mechanism for autophagy mediated death and also a previously unreported mechanism for OHT-induced cytotoxicity in tumor cells. This study also sheds light on the role of Ras stability in mediating tumor cell response to tamoxifen treatment.

Materials and Methods

Antibodies and other reagents

Primary antibodies were obtained from the following sources: H-Ras and N-Ras (Santa Cruz Biotechnology Inc.); Jun N-terminal kinase (JNK), phospho-JNK (Thr183/Tyr185), p44/42, phospho-p44/42 (Thr202/Tyr204), S6, and phospho-S6 ribosomal protein, eIF4E, 4E-BP1, and GAPDH (Cell Signaling Technology); EGFR (Millipore); LC3 (Abgent); and K-Ras (ABD Serotec). Secondary antibodies were horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Bio-Rad) and horse anti-mouse (Cell Signaling Technology); EGFR (Millipore); LC3 (Abgent); and IR dye anti-mouse and anti-rabbit antibodies (Li-Cor Biosciences).

Cytochrome C, rapamycin, and 3-methyladenine (3-MA) were purchased from Sigma. BOC-aspartyl (Ome)-fluoromethyl ketone (BAF) was purchased from MP Biomedicals and batflomycin B1 (BafB1) was from A.G. Scientific. OHT was obtained from Enzo Life Sciences, hygromycin B was from Cellgro, and doxycycline HCL was from Fisher Scientific.

Cell cultures

We have previously described the source of T265-2c, ST88-14, and the 98-0 cells, the human NF1-derived MPNST lines used in this study (18, 29). The identity of these cell lines was routinely verified according to the specifications outlined in the American Type Culture Collection (ATCC) Technical Bulletin 8. Briefly, morphology and doubling times of cells was routinely assessed and the identity of cells was verified by short-tandem repeat analysis. Cells were also regularly tested for Mycoplasma infection. SK-BR-3, MCF7, and MDA-MB-231 breast cancer cells and T84 colon cancer cells were obtained from the ATCC. The colon cancer cell lines Caco2, HCT116, LoVo, HCT-15, RKO, and DLD1 were kindly provided by Dr. Upender Manne [Department of Pathology, University of Alabama at Birmingham (UAB), Birmingham, AL]. The glioma cancer cell lines U87, LN229, and LNX308 were a kind gift from Dr. Yancey Gillespie (UB Division of Neurosurgery) and the pancreatic cancer cell lines Panc1 and MiaPaCa2 were generously provided by Dr. Boris Pasche (UB Division of Hematology and Oncology). Pyrosequencing was conducted to confirm the K-Ras mutational status of the cell lines.

All cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM10; DMEM; Sigma) containing 1% penicillin/streptomycin (Invitrogen), 1% l-glutamine (Sigma), and 10% fetal bovine serum (FBS; Hyclone, Logan, UT) and were incubated at 37°C in a humidified 5% CO₂, 95% air atmosphere. Cells were plated onto uncoated 48-well plates at a density of 15,000/well and in 100 mm dishes at a density of 800,000 cells/dish. Cultures were used in experiments 24 hours post-plating. Drug treatments were carried out in the same media. Cell lines stably transduced with lentiviruses expressing shRNAs were maintained in DMEM supplemented with 10% tetracycline-free FBS (Serum Source International) and hygromycin B (50 μg/mL). During experiments requiring shRNA induction, cells were plated in media without hygromycin B. Twenty-four hours after plating, 2 μg/mL doxycycline HCL was added to induce shRNA expression. Seventy-two hours post-induction, cells were transferred to serum-free media and drug treatments were initiated.

Construction of cell lines stably transduced with lentiviral vectors

Lentiviral vectors carrying cassettes encoding green fluorescent protein (GFP) and miR-like shRNAs under the control of a doxycycline HCL -inducible promoter were constructed using pSLIK vectors (30). Oligonucleotides encoding K-Ras shRNA sequences were designed using the RNAi Codex algorithm. Complementary oligonucleotides were annealed and ligated to BfaI digested p_TTGMiRtc2. The resulting plasmids were recombined with pSLIK-hygro vector using LR Clonase per the manufacturer’s recommendations (Invitrogen). Three lentiviral vectors targeting distinct K-Ras sequences were constructed (pSLC751, pSLC752, and pSLC753 targeting nucleotides 508–530, 224–255, and 406–427 of NM_004985.2, respectively). To identify possible nonspecific activation of RNA-induced silencing complex, a lentiviral vector was also constructed that encodes a shRNA targeting a sequence not present in the human genome (pSLC727). To make lentivirus, pSLIK vectors were transfected into 293FT cells together with helper plasmids (pPLP1, pPLP2, and pVSVg) using Polyfect transfection reagent (Qiagen) per the manufacturer’s recommendations. Seven-two hours posttransfection, virus-containing media was collected and stored at −80°C until use.

To stably transduce lentiviral vectors into T265-2c cells, viral supernatant and 6 μg/mL Polymbrene (Sigma-Aldrich) was added to cells plated in DMEM10 medium in 6-well plates. Twenty-four hours later, virus-containing medium was removed and replaced with tetracycline-free DMEM10. Forty-eight to 72 hours posttransduction, each well was split into three 100-mm dishes and selection with hygromycin begun. Colonies, which arose approximately 2 weeks later, were picked and individually expanded. Lines with appropriate regulation of the shRNA/GFP cassette were initially identified by finding that...
they had no GFP fluorescence in the absence of doxycycline HCl and strong GFP signals following doxycycline HCl induction. To verify that shRNA and GFP expression in the selected lines was appropriately regulated and to establish the optimal conditions for ablation of K-Ras expression, transformants were challenged with 0, 0.25, 0.5, 1.0, or 2.0 μg/ml doxycycline HCl for 72 hours. Lysates of cells stimulated with varying doxycycline HCl concentrations were then immunoblotted and probed with antibodies recognizing GFP and K-Ras.

**Cell viability and in vitro caspase cleavage assays**

The calcein-AM conversion assay used to measure cell viability was conducted as previously described (31). Caspase activation was assessed by the *in vitro* caspase-3 cleavage assay using the chemical substrate DEVD-7-amino-4-methylcoumarin (AMC; BIOMOL).

**Western blotting and 7'-methyl-GTP affinity chromatography**

Whole-cell lysates were prepared by removing the media, washing the cells with PBS, scraping them off and pelleting the cells by centrifugation at 1,750 rpm for 10 minutes. Cell pellets were resuspended in lysis buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA, 1% Triton X-100, 10% glycerol, protease inhibitor cocktail (Sigma), and phosphatase inhibitor cocktails 1 and 3 (Sigma). Lysates were vortexed, clarified, and stored at −80°C. Protein of 40 μg was immunoblotted per our previously described protocol (32). All primary antibodies were diluted to a final concentration of 1:1,000 except GAPDH and EGFR (1:5,000). Immunoreactive species were detected by enhanced chemiluminescence.

7'-Methyl-GTP affinity chromatography was conducted as previously described (33). Signals were detected using ECL Western blotting analysis system (GE Healthcare) and the Odyssey Infrared imaging system (Li-Cor Biosciences).

**RNAi**

Atg7 siRNA was purchased from Thermo Scientific and reconstituted according to manufacturers’ instructions. Cells were plated in DMEM10 and transfected 24 hours postplating using X-tremeGene siRNA transfection reagent (Roche) with a ratio of 5:2 (transfection reagent:oligos). The next day, fresh media was added to cells and after 72 hours, cells were used in experiments.

**Statistics**

All data points represent mean ± SD. *n* = 6 wells for all experiments. All experiments were repeated at least 3 times unless stated otherwise. Representative data are shown. Statistical significance was determined by ANOVA followed by Bonferroni posthoc test. A *P* value less than 0.05 was considered significant.

**Results**

**Caspase activation accompanies but does not mediate OHT-induced death**

OHT effects were examined in T265-2c cells, a human cell line derived from a NF1-associated MPNST. Micromolar concentrations of OHT have been reported to trigger apoptosis, marked by activation of effector caspases such as 3, 6, and 7 (34). Consequently, we first examined the possibility that the death induced by OHT in MPNST cells was apoptotic in nature. To determine whether OHT treatment activated effector caspases in MPNST cells, cells were treated with 8 to 12 μM OHT and, after 48 hours of treatment, the cleavage of DEVD-AMC, a pharmacologic substrate for active effector caspases, was measured in cell lysates. These OHT concentrations were selected as they inhibit the proliferation and survival of breast carcinoma cells and are physiologically relevant to concentrations achieved in patients (35). We found that OHT-treated cells showed a concentration-dependent increase in caspase 3-like enzymatic activity (Fig. 1A). However, a 1-hour pretreatment with a broad spectrum caspase inhibitor failed to attenuate OHT-induced death (Fig. 1B). We conclude that caspase-dependent apoptosis is not the sole mediator of OHT-induced cytotoxicity in MPNST cells.

**OHT induces an autophagic death in MPNST cells**

In other cell types, OHT treatment induces apoptotic features together with large-scale accumulation of AVs (19, 20). Further, a prodeath role has been ascribed to OHT-induced autophagy in breast cancer cells (19). We therefore asked whether OHT triggered the induction of autophagy in MPNST cells. Whole-cell lysates prepared from OHT-treated cultures were probed for changes in levels of LC3 II, a surrogate marker for AV detection. LC3 II, the cleaved and lipidated form of the microtubule associated protein light chain 3 (LC3 or LC3 I) inserts itself in the outer membrane of AVs (36). Relative to untreated cells, OHT-treated cells showed a dramatic increase in steady-state levels of AVs (Fig. 1C). LC3 II can accumulate in response to increased autophagy induction and/or decreased AV degradation. Therefore, autophagic flux was measured in control and OHT-treated cells using BafB1, which inhibits vacuolar ATPase, a molecule active in the late stage of autophagy (37, 38). OHT-treated cells displayed increased autophagic flux, indicating that the increase in steady-state AV levels was due, at least in part, to increased autophagy induction by OHT (Fig. 1D). To assess the functional significance of this phenomenon, we next inhibited the initiation of autophagy by transfecting cells with siRNA targeting Atg7, a critical regulator of AV formation (Fig. 1E). We found that Atg7 knockdown partially protected MPNST cells from OHT-induced death (Fig. 1F). We conclude that OHT triggers autophagic death in MPNST cells.

**OHT triggers K-Ras degradation**

Autophagy plays a critical role in the turnover and recycling of long-lived proteins. Our finding that OHT-induced autophagy mediates death raises the question of whether accelerated degradation of key prosurvival proteins through the autophagy-lysosomal degradation pathway mediates OHT-induced death. A recent genome-wide screen in tamoxifen-treated breast cancer cells identified a number of candidate survival promoting genes present in these cells (27). These genes included the neurofibromin-regulated small GTP-binding protein.
protein K-Ras. Notably, K-Ras is the only neurofibromin-regulated Ras isoform that is targeted to lysosomes for degradation (39). Considered together, these observations led us to hypothesize that OHT triggers autophagic death in MPNST cells by decreasing levels of K-Ras.

We first examined the effects of OHT treatment on K-Ras protein levels in T265-2c cells. Immunoblot analyses showed a concentration-dependent decrease in levels of K-Ras (Fig. 2A). In contrast, levels of H- and N-Ras, which are degraded by proteasomes, remained unaltered following exposure to OHT (Fig. 2B and C). To determine if the decrease in K-Ras levels was due to accelerated degradation, cells were pre-treated for 1 hour with cycloheximide, a protein synthesis inhibitor. In the absence of new protein synthesis, a time-dependent decrease in K-Ras levels was observed in cells treated with both cycloheximide and OHT relative to those treated with cycloheximide alone, indicating that OHT mediates accelerated degradation of K-Ras (Fig. 2D).

To determine whether OHT treatment globally inhibited protein translation, we examined the effect of this treatment on mTOR activity. Levels of phosphorylated S6 kinase, a downstream target of mTOR, did not significantly change 48 hours following OHT treatment (when K-Ras levels are found to decrease), whereas levels of phosphorylated S6 kinase were markedly decreased in cells treated with the mTOR inhibitor rapamycin (Fig. 2E). Cap-dependent translation can also be inhibited by an association between eukaryotic translation initiation factor (eIF4E) and another mTOR target, eIF4E binding protein (4EBP1; ref. 40). Coimmunoprecipitation experiments in vehicle- and OHT-treated cells showed that...
there was no increase in binding of eIF4E and 4EBP1 in these cells, further indicating that OHT treatment did not affect global protein synthesis whereas synthesis was decreased by amino acid starvation (Fig. 2F). In addition, steady-state mRNA levels of K-Ras remained unchanged in OHT-treated cells, indicating that the decrease in K-Ras levels was not due to blocked transcription (data not shown). Considered jointly, these observations indicate that the decrease in K-Ras levels following OHT treatment is due to increased degradation rather than alterations in the transcription or translational machinery of the cells.

**OHT-triggered K-Ras degradation downregulates MAPK signaling**

Several studies have indicated that activated Ras mediates tamoxifen resistance via MAPK activation. Therefore, we examined whether the level of K-Ras degradation observed in OHT-treated MPNST cells is sufficient to inhibit Ras-dependent MAPK activation in these cells. Immuno blot analyses showed that the levels of phosphorylated forms of JNK and p44/42 (Erk1/2) decreased in a time-dependent manner in OHT-treated cells (Fig. 3A and B). We conclude that the degree of K-Ras loss occurring in OHT-treated MPNST cells is sufficient to reduce the activation of at least some Ras-dependent MAPK signaling cascades.

**OHT primes K-Ras for degradation through PKC inhibition**

Our previous study indicated that OHT-induced death of MPNST cells is estrogen receptor independent (18). Consequently, we next attempted to delineate an estrogen receptor-independent mechanism by which OHT primes K-Ras for accelerated degradation. Earlier work has shown that tamoxifen directly binds to and antagonizes the calcium regulated proteins calmodulin and PKC (41–43). Further, calmodulin and PKC are known to differentially modulate the functionality and localization of K-Ras on the plasma membrane (44). These observations led us to hypothesize that inhibition of calmodulin and/or PKC promotes K-Ras degradation. We tested this hypothesis by assessing whether inhibitors of calmodulin or PKC could mimic the OHT-induced degradation of K-Ras. The calmodulin inhibitor
W13 had no effect on steady-state K-Ras levels (Fig. 3C). However, PKC inhibition using R031-8220 triggered a decrease in K-Ras levels under steady state as well as in the absence of new protein synthesis using cycloheximide, indicating that similar to OHT, PKC inhibition also induces accelerated K-Ras degradation (Fig. 3C and D). We conclude that OHT-triggered K-Ras degradation may be a function of its ability to antagonize PKC activity.

Inhibition of autophagy initiation blocks OHT-induced decrease in K-Ras levels

To determine if K-Ras degradation in OHT-treated MPNST cells was mediated by autophagy, we blocked the early stage of autophagy with 3-MA, a class III PI3K inhibitor, and Atg7 knockdown and examined the effect this had on K-Ras levels. A 1 hour pretreatment with 3-MA effectively blocked the OHT-induced decrease in K-Ras levels (Fig. 4A). Similarly, siRNA-mediated knockdown of Atg7 prevented the OHT-mediated decrease in K-Ras levels, whereas the nontargeting control siRNA had no effect (Fig. 4B). Therefore, we conclude that OHT triggers K-Ras degradation through the autophagy pathway.

OHT-induces cytotoxicity through autophagy-mediated K-Ras degradation

To establish that OHT triggers autophagic death in MPNST cells via K-Ras degradation, we assessed the effects of directly depleting K-Ras levels in OHT-treated cells. T265.2c MPNST cells stably transduced with lentiviral vectors expressing either K-Ras (T53N) or control (T27A) shRNAs under a doxycycline-responsive promoter were generated. We found that cells expressing K-Ras shRNA showed increased sensitivity to OHT in the presence of doxycycline (Fig. 4C). In contrast, the addition of doxycycline had no effect on cells expressing control shRNA (Fig. 4D). This is in keeping with previously published reports indicating that K-Ras plays a prosurvival role in the context of tamoxifen-induced death (27). Thus, we conclude that OHT triggers death in MPNST cells, at least in part, via autophagy-mediated K-Ras degradation.

OHT also triggers EGFR degradation

Next, we examined whether OHT also affects the stability of membrane-associated proteins such as EGFR that have been shown to colocalize with K-Ras en route to degradation (39). In response to growth factor stimulation, K-Ras and EGFR are internalized and occupy the same signaling scaffolds followed by degradation. Therefore, we tested the possibility that in addition to K-Ras, OHT might also trigger a decrease in EGFR stability and observed a time-dependent decrease in levels of EGFR in the presence of cycloheximide indicating that this decrease was due to accelerated degradation (Fig. 5A). Given the relevance of EGFR to malignant gliomas, we assessed the effects of OHT on EGFR levels in multiple glioma and MPNST cell lines and observed a concentration-dependent decrease in all cell lines (Fig. 5B–E). Similar results were obtained for the breast cancer line MCF7 (Fig. 5F). These results indicate that, in addition to K-Ras, OHT also influences EGFR stability.

OHT triggers K-Ras degradation in multiple tumor types

Finally, we wanted to determine whether the OHT effects on K-Ras that we observed in MPNST cells occurred more generally in other tumor types. We consistently observed an OHT-induced decrease in K-Ras levels across a panel of cell lines derived from multiple tumor types (Fig. 6A–I). Given the clinical relevance of tamoxifen to breast cancer, multiple breast cancer cell lines were also examined. We observed that OHT triggered a concentration-dependent decrease in K-Ras in the SK-BR-3 and MCF7 but not in MDA-MB-231 cells (Figs. 6H and I and 7A). Previously, mutations in Ras isoforms have been shown to influence their ubiquitination

Figure 3. OHT treatment inhibits MAPK signaling. Whole-cell lysates from OHT-treated cells show a time-dependent decrease in levels of phospho-p44/42 (A) and phospho-JNK (B). C, treatment with the PKC inhibitor R031-8220 (10 μmol/L, 24 hours) and OHT (10 μmol/L, 24 hours) caused a decrease, whereas the calmodulin inhibitor W13 (15 μg/mL, 24 hours) had no effect on steady-state K-Ras levels. D, whole-cell lysates from R031-8220-treated cells showed a time-dependent decrease in K-Ras levels in the presence of the protein synthesis inhibitor CHX (100 μmol/L, 1 hour pretreatment).
patterns and stability (45). This led us to test the hypothesis that OHT-induced K-Ras degradation may be affected by the mutational status of K-Ras.

Consistent with previously published studies, our pyrosequencing analysis revealed that while the SK-BR-3 and MCF7 cells harbor a wild-type K-Ras, the MDA-MB-231 cells have a mutation in codon 13 (G13D). To assess whether cell lines harboring a mutant K-Ras (G13D) are relatively resistant to K-Ras degradation, we tested multiple colon cancer cell lines as the G13D mutation is commonly associated with colon cancer. We observed that OHT triggered a concentration-dependent decrease in K-Ras in the colon cancer cell lines Caco2 and RKO, which have a wild-type K-Ras (Fig. 6F and G). However, the cell lines DLD1, HCT-15, HCT 116, and LoVo that bear a G13D mutation were relatively resistant to K-Ras degradation (Fig. 7B–E). These results indicate that while OHT can target K-Ras for degradation in multiple tumor types, the effects of OHT on K-Ras stability may be influenced by the mutation status of K-Ras. However, the colon cancer line T84 that also harbors a G13D mutation did show a decrease in K-Ras levels following OHT addition, indicating that additional factors might co-operate to determine the response of these cell lines to OHT treatment (Fig. 7F).

Discussion

The goal of this study was to identify the molecular mechanisms that mediate estrogen receptor independent OHT-induced cytotoxicity in MPNST cells (18). This study offers evidence to support the hypothesis that the autophagic pathway is a critical mediator of OHT-induced death. Briefly, we show that caspases are activated following OHT treatment but are not the primary mediators of death. OHT triggers an increase in autophagic flux thereby impacting the autophagy pathway. Blocking autophagy initiation attenuates OHT-induced death, indicating a prodeath role for autophagy in this setting. Furthermore, we have shown that through its inhibitory effects on PKC, OHT primes K-Ras for degradation in an autophagy-dependent manner. Hence, autophagy mediates death in OHT-treated cells, at least in part, through accelerated K-Ras degradation. This finding was extended to other tumor types and it was observed that OHT-mediated K-Ras degradation is affected by the mutational status of K-Ras. Thus, this study provides an

![Figure 4. Autophagy mediates OHT-induced death through K-Ras degradation.](image-url)
insight into the role of altered protein turnover by autophagy as a death mechanism.

The role of therapy-induced autophagy in cancer remains paradoxical. It is now well accepted that in response to various chemotherapeutic drugs, radiation, and targeted therapeutics, dying cells display large-scale accumulation of autophagic vacuoles (46). OHT is widely accepted as a potent autophagy inducer. In keeping with this, we observed an increase in autophagic flux following OHT treatment. This might result from the transient block in mTOR activity that was observed 24 hours following OHT treatment. We tested the role of OHT-induced autophagy by knocking down Atg7 and observed significant protection from OHT-induced death, thus establishing a pro-death role for autophagy.

Next, we attempted to delineate the underlying mechanism for autophagy-mediated death in the context of OHT. While the scope of autophagy has expanded dramatically to include diverse functions, the most basic role of autophagy remains the turnover of long-lived proteins. There exists a delicate balance between prosurvival and death-promoting proteins in the cell. We hypothesized that autophagy can regulate death by altering the rates of degradation of these proteins and disrupting the existing balance. This may offer an explanation for the context-dependent roles of autophagy in response to different therapeutic agents. Accordingly, we proposed that OHT-induced increase in autophagic flux might accelerate the degradation of K-Ras, a protein shown to mediate resistance to tamoxifen-induced death (27). We tested this hypothesis by examining the effects of OHT on the rate of K-Ras degradation and observed accelerated degradation in OHT-treated cells. Pharmacologic inhibition using 3-MA and transient knockdown of Atg7 blocked the OHT-induced decrease in K-Ras levels indicating that K-Ras undergoes autophagic degradation. The functional relevance of this observation was established by assessing the effects of K-Ras degradation on downstream MAPK signaling. Modulation of protein turnover by drug-induced autophagy has not been previously established, thereby providing us with new insights on the role of autophagy in mediating death.

Next, we examined the possibility that OHT might specifically prime K-Ras for degradation through the autophagy pathway. Tamoxifen is known to bind to calmodulin and PKC and inhibit their functioning (47). Interestingly, PKC inhibition could simulate the effects of OHT on K-Ras degradation giving rise to the possibility that OHT might prime K-Ras for degradation through PKC inhibition. We also tested the possibility...
that OHT triggers the degradation of additional prosurvival proteins apart from K-Ras, especially other membrane-associated proteins. EGFR and its family members are constitutively activated in MPNST cells and knockdown of EGFR signaling is associated with decreased proliferation and survival in MPNSTs cells thereby making it an attractive therapeutic target in this tumor type (29). We observed that similar to K-Ras, EGFR underwent accelerated degradation. However, it remains to be tested whether K-Ras and EGFR follow a similar degradation path and/or are primed for degradation through a similar upstream stimulus that alters membrane dynamics.

To assess the relevance of our results to other tumor types, we tested the ability of OHT to induce K-Ras and EGFR degradation in cell lines derived from different tumor types. In addition, we explored the possibility that mutations in K-Ras can influence its degradation. This is an important consideration since K-Ras mutations underlie the pathogenesis of several aggressive malignancies. We found that, unlike wild-type K-Ras, K-RasG13D was resistant to OHT-mediated degradation in nearly all cell lines tested. However, the results obtained for the colon cancer line T84 (K-RasG13D), which remained sensitive to OHT-induced K-Ras degradation, indicate that additional factors influence the stability of K-Ras following OHT treatment.

In summary, the findings of this study reveal yet another estrogen receptor-independent mechanism for OHT-induced cell death. This article also unveils a novel mechanism for autophagy mediated death and points toward the existence of a mechanism by which mutant K-Ras might resist autophagic degradation. Additional studies are now needed to examine the clinical relevance of these findings.

**Figure 6.** OHT triggers K-Ras degradation in multiple tumor types. Whole-cell lysates from glioma (A), MPNST (B and C), pancreatic (D and E), colon (F and G), and breast cancer (H and I) cell lines showed a decrease in K-Ras levels following OHT treatment (48 hours).
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: K.A. Roth, L. Kohli, N.M. Brossier, M.A. Bjornsti, S.L. Carroll
Development of methodology: K.A. Roth, L. Kohli, N. Kaza, S.J. Byer, S.L. Carroll
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): L. Kohli, N. Kaza, T. Coric, S.J. Byer, B.J. Klocke, S.L. Carroll
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K.A. Roth, L. Kohli, N. Kaza, T. Coric, S.J. Byer, S.L. Carroll
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): N. Kaza
Writing, review, and/or revision of the manuscript: K.A. Roth, T. Coric, N.M. Brossier, M.A. Bjornsti, S.L. Carroll
Study supervision: K.A. Roth, L. Kohli, S.L. Carroll

Acknowledgments
The authors thank Dr. Upender Manne and Dr. Boris Pasche for generously providing us with the colon and pancreatic cancer cell lines and Dr. Michael Crowley at the Hellin Center for Genomic Sciences at UAB for pyrosequencing.

Grant Support
This work was supported by NIH grants R01 NS041962 (K.A. Roth), R01 CA134773 (K.A. Roth. and S.L. Carroll), R01 CA122804 (S.L. Carroll), F30 NS063626 (N.M. Brossier), and P50CA890919 (T. Coric and M.A. Bjornsti); and Department of Defense Grants X81XWH-09-1-0086 and X81XWH-12-1-0164 (S.L. Carroll).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 2, 2012; revised March 15, 2013; accepted April 28, 2013; published OnlineFirst May 30, 2013.

References


Figure 7. Mutant K-Ras resists OHT-induced degradation. Lysates from breast (A) and colon cancer (B-E) cell lines harboring a G13D mutation failed to show a decrease in K-Ras levels following OHT treatment (48 hours). F, the colon cancer cell line T84 (G13D) was an exception.
Autophagic Death by K-Ras Degradation

32. Lamm HY. Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 1984;118:27–32.
4-Hydroxytamoxifen Induces Autophagic Death through K-Ras Degradation

Latika Kohli, Niroop Kaza, Tatjana Coric, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-12-3765

Cited articles
This article cites 47 articles, 20 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/14/4395.full#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/73/14/4395.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/73/14/4395.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.